Phenotype
|
Fish
|
Conditions
|
Figures
|
supraintestinal artery Kaede expression decreased amount, abnormal
|
ci49Tg/ci49Tg + MO1-etsrp + MO2-etsrp
|
light intensity
|
Fig. 5
from Metikala et al., 2022
|
supraintestinal artery decreased amount, abnormal
|
ci49Tg/ci49Tg + MO1-etsrp + MO2-etsrp
|
light intensity
|
Fig. 5
from Metikala et al., 2022
|
extension tal1 expression decreased amount, abnormal
|
ci49Tg/ci49Tg + MO1-etsrp + MO2-etsrp
|
light intensity
|
Fig. 5
from Metikala et al., 2022
|
extension inserted into supraintestinal artery, abnormal
|
ci49Tg/ci49Tg + MO1-etsrp + MO2-etsrp
|
light intensity
|
Fig. 5
from Metikala et al., 2022
|
posterior lateral mesoderm morphology, abnormal
|
AB + MO2-etsrp
|
standard conditions
|
Fig. 4
from Liu et al., 2008
|
embryonic hemopoiesis disrupted, abnormal
|
AB + MO2-etsrp
|
standard conditions
|
Fig. 4
from Liu et al., 2008
|
endothelial cell cdh5 expression absent, abnormal
|
WT + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
endothelial cell absent, abnormal
|
WT + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
myeloid cell differentiation disrupted, abnormal
|
WT + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 2
from Sumanas et al., 2008
|
posterior caudal vein flt4 expression decreased amount, abnormal
|
WT + MO2-etsrp
|
control
|
Fig. 6
from Davis et al., 2018
|
posterior caudal vein lyve1b expression decreased amount, abnormal
|
WT + MO2-etsrp
|
control
|
Fig. 6
from Davis et al., 2018
|
embryonic blood vessel endothelial progenitor cell kdrl expression decreased amount, abnormal
|
WT + MO2-etsrp
|
standard conditions
|
Fig. 4
from Pociute et al., 2019
|
embryonic blood vessel endothelial progenitor cell cdh5 expression decreased amount, abnormal
|
WT + MO2-etsrp
|
standard conditions
|
Fig. 4
from Pociute et al., 2019
|
blood vessel morphogenesis disrupted, abnormal
|
WT + MO2-etsrp
|
standard conditions
|
Fig. S2
from Herpers et al., 2008
|
regulation of myeloid leukocyte differentiation disrupted, abnormal
|
WT + MO2-etsrp
|
standard conditions
|
Fig. 4
from Bukrinsky et al., 2009
|
blood vasculature morphology, abnormal
|
WT + MO2-etsrp
|
standard conditions
|
Fig. S2
from Herpers et al., 2008
|
whole organism neoplasm has fewer parts of type blood vessel, abnormal
|
ci5Tg + MO2-etsrp
|
ultraviolet light, cancer xenotransplantation
|
Fig. 7
from Baltrunaite et al., 2017
|
intersegmental vessel sprouting angiogenesis decreased process quality, abnormal
|
ci6Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 2
from Craig et al., 2015
|
blood vessel development disrupted, abnormal
|
s843Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 3
from Chou et al., 2013
|
dorsal aorta absent, abnormal
|
s843Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 3
from Chou et al., 2013
|
intersegmental vessel EGFP expression absent, abnormal
|
s843Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. S5
from Reischauer et al., 2016
|
blood vasculature lacks parts or has fewer parts of type blood vessel, abnormal
|
s843Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. S5
from Reischauer et al., 2016
|
caudal vein plexus EGFP expression decreased amount, abnormal
|
s843Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. S5
from Reischauer et al., 2016
|
intersegmental vessel EGFP expression decreased distribution, abnormal
|
s843Tg + MO2-etsrp
|
control
|
Fig. 2 ,
Fig. 7
from Chetty et al., 2020
|
blood vasculature EGFP expression decreased distribution, abnormal
|
s843Tg + MO2-etsrp
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
blood vessel EGFP expression spatial pattern, abnormal
|
s843Tg + MO2-etsrp
|
control
|
Fig. 2 ,
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel EGFP expression spatial pattern, abnormal
|
s843Tg + MO2-etsrp
|
control
|
Fig. 2 ,
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel EGFP expression spatial pattern, abnormal
|
s843Tg + MO2-etsrp
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
blood vessel EGFP expression decreased distribution, abnormal
|
s843Tg + MO2-etsrp
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
blood vasculature EGFP expression spatial pattern, abnormal
|
s843Tg + MO2-etsrp
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel decreased height, abnormal
|
s843Tg + MO2-etsrp
|
control
|
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel irregular spatial pattern, abnormal
|
s843Tg + MO2-etsrp
|
control
|
Fig. 2 ,
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel height, exacerbated
|
s843Tg + MO2-etsrp
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
sprouting angiogenesis delayed, abnormal
|
s843Tg + MO2-etsrp
|
standard conditions
|
Fig. 4
from Pociute et al., 2019
|
angiogenic sprout mislocalised, abnormal
|
s843Tg + MO2-etsrp
|
standard conditions
|
Fig. 4
from Pociute et al., 2019
|
intersegmental vessel decreased amount, abnormal
|
s843Tg + MO2-etsrp
|
control
|
Fig. 2 ,
Fig. 7
from Chetty et al., 2020
|
blood vessel EGFP expression spatial pattern, abnormal
|
s843Tg + MO2-etsrp
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel amount, exacerbated
|
s843Tg + MO2-etsrp
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
blood vasculature structure, abnormal
|
s843Tg + MO2-etsrp
|
control
|
Fig. 2
from Chetty et al., 2020
|
blood vessel EGFP expression decreased distribution, abnormal
|
s843Tg + MO2-etsrp
|
control
|
Fig. 2 ,
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel EGFP expression decreased distribution, abnormal
|
s843Tg + MO2-etsrp
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
blood vasculature EGFP expression decreased distribution, abnormal
|
s843Tg + MO2-etsrp
|
control
|
Fig. 2 ,
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel angiogenic sprout decreased length, abnormal
|
s843Tg + MO2-etsrp
|
standard conditions
|
Fig. 4
from Pociute et al., 2019
|
intersegmental vessel spatial pattern, exacerbated
|
s843Tg + MO2-etsrp
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
blood vasculature EGFP expression spatial pattern, abnormal
|
s843Tg + MO2-etsrp
|
control
|
Fig. 2 ,
Fig. 7
from Chetty et al., 2020
|
vascular endothelium mislocalised, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 2
from Chou et al., 2010
|
dorsal aorta absent, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 2
from Chou et al., 2010
|
interrenal primordium left side unfused from interrenal primordium right side, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 2
from Chou et al., 2010
|
intersegmental vessel spatial pattern, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
interrenal primordium bilateral, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 2
from Chou et al., 2010
|
posterior cardinal vein absent, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 2
from Chou et al., 2010
|
vasculogenesis process quality, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
intersegmental vessel absent, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
dorsal aorta decreased size, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 2
from Chou et al., 2010
|
axial vasculature apoptotic process increased process quality, abnormal
|
y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 6
from Craig et al., 2015
|
endothelial cell EGFP expression absent, abnormal
|
y1Tg + MO2-etsrp
|
control
|
Fig. 5
from Chetty et al., 2020
|
posterior cardinal vein absent, abnormal
|
y1Tg + MO2-etsrp
|
control
|
Fig. 4
from Qiu et al., 2016
|
vasculature EGFP expression increased amount, abnormal
|
y1Tg + MO2-etsrp
|
cancer xenotransplantation
|
Fig. 5
from Baltrunaite et al., 2017
|
dorsal aorta absent, abnormal
|
y1Tg + MO2-etsrp
|
control
|
Fig. 4
from Qiu et al., 2016
|
whole organism neoplasm lacks all parts of type angiogenic sprout, abnormal
|
y1Tg + MO2-etsrp
|
ultraviolet light, cancer xenotransplantation
|
Fig. 5
from Baltrunaite et al., 2017
|
whole organism neoplasm decreased size, abnormal
|
y1Tg + MO2-etsrp
|
ultraviolet light, cancer xenotransplantation
|
Fig. 5
from Baltrunaite et al., 2017
|
vasculature EGFP expression increased amount, abnormal
|
y1Tg + MO2-etsrp
|
ultraviolet light, cancer xenotransplantation
|
Fig. 5
from Baltrunaite et al., 2017
|
whole organism neoplasm EGFP expression decreased amount, abnormal
|
y1Tg + MO2-etsrp
|
ultraviolet light, cancer xenotransplantation
|
Fig. 5
from Baltrunaite et al., 2017
|
thoracic duct EGFP expression absent, abnormal
|
y1Tg + MO2-etsrp
|
standard conditions
|
Fig. 4
from Davis et al., 2018
|
thoracic duct absent, abnormal
|
y1Tg + MO2-etsrp
|
standard conditions
|
Fig. 4
from Davis et al., 2018
|
intestine decreased size, abnormal
|
zf346Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 3
from Chou et al., 2013
|
dorsal aorta absent, abnormal
|
zf346Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 3
from Chou et al., 2013
|
blood vessel development disrupted, abnormal
|
zf346Tg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 3
from Chou et al., 2013
|
vascular lymphangioblast absent, abnormal
|
ci5Tg; y1Tg + MO2-etsrp
|
standard conditions
|
Fig. 3
from Davis et al., 2018
|
thoracic duct EGFP expression absent, abnormal
|
ci5Tg; y1Tg + MO2-etsrp
|
standard conditions
|
Fig. 3
from Davis et al., 2018
|
trunk vasculature morphology, abnormal
|
ci5Tg; y1Tg + MO2-etsrp
|
standard conditions
|
Fig. 3
from Davis et al., 2018
|
lymphangiogenesis decreased occurrence, abnormal
|
ci5Tg; y1Tg + MO2-etsrp
|
standard conditions
|
Fig. 3
from Davis et al., 2018
|
thoracic duct absent, abnormal
|
ci5Tg; y1Tg + MO2-etsrp
|
standard conditions
|
Fig. 3
from Davis et al., 2018
|
vascular lymphangioblast EGFP expression absent, abnormal
|
ci5Tg; y1Tg + MO2-etsrp
|
standard conditions
|
Fig. 3
from Davis et al., 2018
|
intersegmental vessel EGFP expression decreased distribution, abnormal
|
is4Tg; s843Tg + MO2-etsrp
|
control
|
Fig. 3
from Chetty et al., 2020
|
intersegmental vessel EGFP expression spatial pattern, abnormal
|
is4Tg; s843Tg + MO2-etsrp
|
control
|
Fig. 3
from Chetty et al., 2020
|
blood vessel EGFP expression spatial pattern, abnormal
|
is4Tg; s843Tg + MO2-etsrp
|
control
|
Fig. 3
from Chetty et al., 2020
|
blood vessel EGFP expression decreased distribution, abnormal
|
is4Tg; s843Tg + MO2-etsrp
|
control
|
Fig. 3
from Chetty et al., 2020
|
axial blood vessel blood vessel endothelial cell decreased amount, abnormal
|
is4Tg; s843Tg + MO2-etsrp
|
control
|
Fig. 3
from Chetty et al., 2020
|
blood vasculature EGFP expression spatial pattern, abnormal
|
is4Tg; s843Tg + MO2-etsrp
|
control
|
Fig. 3
from Chetty et al., 2020
|
blood vasculature EGFP expression decreased distribution, abnormal
|
is4Tg; s843Tg + MO2-etsrp
|
control
|
Fig. 3
from Chetty et al., 2020
|
vascular lymphangioblast decreased amount, abnormal
|
nim5Tg; nkuasgfp1aTg + MO2-etsrp
|
standard conditions
|
Fig. 5
from Davis et al., 2018
|
thoracic duct TagRFP expression absent, abnormal
|
nim5Tg; y1Tg + MO2-etsrp
|
standard conditions
|
Fig. 3
from Davis et al., 2018
|
trunk vasculature morphology, abnormal
|
nim5Tg; y1Tg + MO2-etsrp
|
control
|
Fig. 3
from Davis et al., 2018
|
thoracic duct absent, abnormal
|
nim5Tg; y1Tg + MO2-etsrp
|
standard conditions
|
Fig. 3
from Davis et al., 2018
|
blood cell decreased amount, abnormal
|
sd2Tg; tsu2013Tg + MO2-etsrp
|
control
|
Fig. 4
from Qiu et al., 2016
|
embryonic blood vessel endothelial progenitor cell cdh5 expression decreased distribution, abnormal
|
clec14aci15/ci15 + MO2-etsrp
|
standard conditions
|
Fig. 4
from Pociute et al., 2019
|
embryonic blood vessel endothelial progenitor cell kdrl expression decreased distribution, abnormal
|
clec14aci15/ci15 + MO2-etsrp
|
standard conditions
|
Fig. 4
from Pociute et al., 2019
|
embryonic blood vessel endothelial progenitor cell cdh5 expression decreased amount, abnormal
|
clec14aci15/ci15 + MO2-etsrp
|
standard conditions
|
Fig. 4
from Pociute et al., 2019
|
embryonic blood vessel endothelial progenitor cell kdrl expression decreased amount, abnormal
|
clec14aci15/ci15 + MO2-etsrp
|
standard conditions
|
Fig. 4
from Pociute et al., 2019
|
endothelial cell cdh5 expression absent, abnormal
|
gfi1aaqmc551Gt/qmc551Gt + MO2-etsrp
|
standard conditions
|
Fig. 5
from Moore et al., 2018
|
erythroid lineage cell alas2 expression amount, ameliorated
|
gfi1aaszy5/szy5 + MO2-etsrp
|
standard conditions
|
FIGURE 4
from Wu et al., 2022
|
endothelial cell kdrl expression amount, ameliorated
|
gfi1aaszy5/szy5 + MO2-etsrp
|
standard conditions
|
FIGURE 4
from Wu et al., 2022
|
erythroid lineage cell alas2 expression amount, ameliorated
|
gfi1aaszy5/szy5 + MO2-etsrp + MO5-sox7
|
standard conditions
|
FIGURE 4
from Wu et al., 2022
|
endothelial cell kdrl expression amount, ameliorated
|
gfi1aaszy5/szy5 + MO2-etsrp + MO5-sox7
|
standard conditions
|
FIGURE 4
from Wu et al., 2022
|
endothelial cell cdh5 expression absent, abnormal
|
WT + MO1-etsrp + MO1-gna13a + MO1-gna13b + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
myocardium fused with myocardium, ameliorated
|
WT + MO1-etsrp + MO1-gna13a + MO1-gna13b + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
endothelial cell absent, abnormal
|
WT + MO1-etsrp + MO1-gna13a + MO1-gna13b + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
myocardial precursor cardioblast migration to the midline involved in heart field formation occurrence, ameliorated
|
WT + MO1-etsrp + MO1-gna13a + MO1-gna13b + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
sprouting angiogenesis delayed, exacerbated
|
clec14aci15/ci15; s843Tg + MO2-etsrp
|
standard conditions
|
Fig. 4
from Pociute et al., 2019
|
angiogenic sprout mislocalised, exacerbated
|
clec14aci15/ci15; s843Tg + MO2-etsrp
|
standard conditions
|
Fig. 4
from Pociute et al., 2019
|
intersegmental vessel angiogenic sprout decreased length, exacerbated
|
clec14aci15/ci15; s843Tg + MO2-etsrp
|
standard conditions
|
Fig. 4
from Pociute et al., 2019
|
intersegmental vessel EGFP expression decreased distribution, abnormal
|
ets1ci14/ci14; is4Tg; s843Tg + MO2-etsrp
|
control
|
Fig. 3
from Chetty et al., 2020
|
intersegmental vessel EGFP expression spatial pattern, abnormal
|
ets1ci14/ci14; is4Tg; s843Tg + MO2-etsrp
|
control
|
Fig. 3
from Chetty et al., 2020
|
blood vessel EGFP expression spatial pattern, abnormal
|
ets1ci14/ci14; is4Tg; s843Tg + MO2-etsrp
|
control
|
Fig. 3
from Chetty et al., 2020
|
blood vessel EGFP expression decreased distribution, abnormal
|
ets1ci14/ci14; is4Tg; s843Tg + MO2-etsrp
|
control
|
Fig. 3
from Chetty et al., 2020
|
axial blood vessel blood vessel endothelial cell decreased amount, abnormal
|
ets1ci14/ci14; is4Tg; s843Tg + MO2-etsrp
|
control
|
Fig. 3
from Chetty et al., 2020
|
blood vasculature EGFP expression spatial pattern, abnormal
|
ets1ci14/ci14; is4Tg; s843Tg + MO2-etsrp
|
control
|
Fig. 3
from Chetty et al., 2020
|
blood vasculature EGFP expression decreased distribution, abnormal
|
ets1ci14/ci14; is4Tg; s843Tg + MO2-etsrp
|
control
|
Fig. 3
from Chetty et al., 2020
|
intersegmental vessel EGFP expression decreased distribution, abnormal
|
ets1ci14/ci14; s843Tg + MO2-etsrp
|
control
|
Fig. 2
from Chetty et al., 2020
|
intersegmental vessel EGFP expression spatial pattern, abnormal
|
ets1ci14/ci14; s843Tg + MO2-etsrp
|
control
|
Fig. 2
from Chetty et al., 2020
|
blood vessel EGFP expression spatial pattern, abnormal
|
ets1ci14/ci14; s843Tg + MO2-etsrp
|
control
|
Fig. 2
from Chetty et al., 2020
|
blood vasculature structure, abnormal
|
ets1ci14/ci14; s843Tg + MO2-etsrp
|
control
|
Fig. 2
from Chetty et al., 2020
|
blood vessel EGFP expression decreased distribution, abnormal
|
ets1ci14/ci14; s843Tg + MO2-etsrp
|
control
|
Fig. 2
from Chetty et al., 2020
|
intersegmental vessel irregular spatial pattern, abnormal
|
ets1ci14/ci14; s843Tg + MO2-etsrp
|
control
|
Fig. 2
from Chetty et al., 2020
|
blood vasculature EGFP expression spatial pattern, abnormal
|
ets1ci14/ci14; s843Tg + MO2-etsrp
|
control
|
Fig. 2
from Chetty et al., 2020
|
intersegmental vessel decreased amount, abnormal
|
ets1ci14/ci14; s843Tg + MO2-etsrp
|
control
|
Fig. 2
from Chetty et al., 2020
|
blood vasculature EGFP expression decreased distribution, abnormal
|
ets1ci14/ci14; s843Tg + MO2-etsrp
|
control
|
Fig. 2
from Chetty et al., 2020
|
skeletal muscle cell differentiation increased occurrence, abnormal
|
etsrpci32Gt/+; nkuasgfp1aTg + MO1-etsrp + MO2-etsrp
|
standard conditions
|
Fig. 3
from Chestnut et al., 2020
|
intersegmental vessel sprouting angiogenesis arrested, abnormal
|
fli1rstpl50Gt/+; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
vasculogenesis process quality, abnormal
|
fli1rstpl50Gt/+; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
intersegmental vessel absent, abnormal
|
fli1rstpl50Gt/+; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
intersegmental vessel sprouting angiogenesis arrested, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
axial vasculature malformed, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
axial vasculature apoptotic process increased process quality, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 6
from Craig et al., 2015
|
vasculogenesis process quality, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
axial vasculature vasculogenesis process quality, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
intersegmental vessel absent, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO1-etsrp + MO2-etsrp
|
control
|
Fig. 3
from Craig et al., 2015
|
whole organism neoplasm EGFP expression decreased amount, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO2-etsrp
|
ultraviolet light, cancer xenotransplantation
|
Fig. 6
from Baltrunaite et al., 2017
|
whole organism neoplasm lacks all parts of type angiogenic sprout, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO2-etsrp
|
ultraviolet light, cancer xenotransplantation
|
Fig. 6
from Baltrunaite et al., 2017
|
whole organism neoplasm lacks parts or has fewer parts of type blood vessel, abnormal
|
fli1rstpl50Gt/tpl50Gt; y1Tg + MO2-etsrp
|
ultraviolet light, cancer xenotransplantation
|
Fig. 6
from Baltrunaite et al., 2017
|
endothelial cell absent, abnormal
|
fb9Tg; y1Tg + MO1-etsrp + MO1-gna13a + MO1-gna13b + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
endothelial cell EGFP expression absent, abnormal
|
fb9Tg; y1Tg + MO1-etsrp + MO1-gna13a + MO1-gna13b + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|
myocardial precursor cardioblast migration to the midline involved in heart field formation occurrence, ameliorated
|
fb9Tg; y1Tg + MO1-etsrp + MO1-gna13a + MO1-gna13b + MO2-etsrp
|
standard conditions
|
Fig. 8
from Xie et al., 2016
|